CD274 and esophageal squamous cell carcinoma: Recently, ASTRUM-007, a randomized, double-blind, phase III clinical trial conducted at 70 hospitals in China, assessed the efficacy and safety of serplulimab plus chemotherapy compared with mono-chemotherapy as the first-line treatment of advanced or metastatic ESCC patients with PD-L1 combined positive score (CPS) ≥ 1 (10).